Watson launches four new products
California, USA-based Watson Pharmaceuticals has introduced four newbranded drugs through its newly-realigned sales force, it was announced at the 19th annual JP Morgan H&Q Healthcare conference in San Francisco earlier this month.
Three new pain management products, Maxidone and Norco 5.0mg and Norco 7.5mg (hydrocodone bitartrate/acetaminophen), were launched to the primary care marketplace by the group's general products division and these will represent an estimated $40 million in revenues for 2001.
The fourth product, Unithroid (levothyroxine sodium), was introduced by the group's general products and women's health division for the treatment of hypothyroidism. Based on market size and the current competitive environment, Watson estimates that Unithroid will achieve sales of around $15 million this year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze